Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Insurance coverage should precede rather than follow clinical validation of broad genomic testing in oncology. More extensive testing of cancer patients during the course of care would do more than improve treatment selection for those patients. The information gathered from testing, linked to knowledge of the clinical course of patients with a variety of neoplastic diseases and assembled into well-designed databases, could also change diagnostic categories, improve the accuracy of prognosis, and provide guidance for treatment of patients with similar profiles.”
Rebecca Eisenberg and Harold Varmus December 1, 2017 Science, Policy Forum

Rebecca Eisenberg will present at PMWC 2018 Michigan during the “Economics and Socio-Political Aspects of Precision Medicine” session – Program.

Starting now, CMS (Centers for Medicare & Medicaid Services) will cover the costs of cancer gene tests that have been approved by the Food and Drug Administration. At this point the CMS will only cover these tests for patients with Stage 3 and 4 cancer. In addition to tracking outcomes, this testing will generate large volumes of genomic cancer data.

This data will help Medicare in addition to hospitals and companies who are gathering evidence to validate their own tests. It will also allow pharma companies to fill their targeted treatment trials with “genetically-matched” patients. This data will have a significant impact on better patient care and on the future of precision medicine.

Recently, the FDA made strides in streamlining the development and review pathway for consumer tests that evaluate genetic health risks, approving among others:

  • Foundation Medicine’s FoundationOne CDx (F1CDx)
  • Thermo Fisher Oncomine Dx Target Test for lung cancer
  • Agilent’s GenetiSure Dx tests
  • Illumina’s Extended RAS panel cancer companion diagnostic test for colorectal cancer

Healthcare continues to undergo revolutionary changes driven by new technologies and innovations that result in new therapies and significant treatment advancements. At the same time, higher costs associated with these developments heighten the challenge of leveling the playing field as it pertains to Precision Medicine for all.  We can’t lose sight of our goal to bring these treatment options to all patients as we reshape medicine.

Relevant reimbursement topics will take center stage in the Day 1, afternoon session at PMWC 2018 Michigan, June 6 and 7, 2018, “The Economics and Socio-Political Aspects of Precision Medicine”. Contributing experts include:

Steve Nelson
CEO, United Healthcare

Amir Dan Rubin
CEO, One Medical

Rebecca Eisenberg
Professor of Law, University of Michigan

Join us for this highly relevant session with leading experts across the industry!

Interview with Dan Rhodes from Strata Oncology

Q: What need is Strata Oncology addressing?

Despite substantial advances in precision oncology, the majority of advanced cancer patients still do not benefit from comprehensive tumor molecular profiling or precision therapy trials.

Read More

Interview with Lisa McLaughlin from Workit Health

Q: What need is Workit Health addressing?

Drug overdoses killed more Americans last year than were lost during the entire Vietnam War (69,000).

Read More

Interview with Olivier Elemento from Weill Cornell Medicine

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

I direct the Englander Institute for Precision Medicine, an Institute that focuses on using genomics and informatics to make medicine more individualized.

Read More

Interview with Dr. Dunnenberger from NorthShore University HealthSystem

Q: What patient population is NorthShore University HealthSystem serving and which services are you specializing in?

NorthShore is a four hospital community health system with over 100 outpatient medical offices.

Read More

How Artificial Intelligence (AI) Will Potentiate Individualized Medicine

We had the chance to sit down with Dr. Topol to hear his thoughts on big data, digital health, sensors, and artificial intelligence, some of the newest precision medicine technologies.

Read More

Interview with Jennifer Kloke from Ayasdi

Q: What need is Ayasdi addressing?

Ayasdi is pioneering the application of AI to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Q&A with Eric Topol, Executive Vice President, Scripps Research Institute

Dr. Eric Topol, voted by Modern Healthcare as the most influential physician executive in the United States, shared his thoughts on why people should own and control their own data.

Read More

CMS to Approve Coverage of NGS-based Cancer Testing | Big Pharma’s Response & The effect on PM

Why this is a Big Deal? As we know, private insurers follow suit once Medicare makes a decision such as this. This portends well for genetic testing to become routine standard of care for patients with advanced cancers.

Read More

Q&A with Mickey Kertesz, Chief Executive Officer, Karius

Q: Tell us a little bit about Karius – what problem(s)/need(s) are you trying to address and what technology is behind it to achieve this?

Read More

Join PMWC 2018 Michigan This June to Learn More about How the Modulation of the Epigenome Increases the Risk for Type 2 Diabetes

Dr. Michael Boehnke (University of Michigan) – who pioneered large-scale studies identifying genetic risk in diabetes and bipolar disorder – shared with us some recent insights about recent advances in exome and genome sequencing and their applications to better understand disease biology and etiology of psychiatric disorders

Read More

AI and Machine Learning in Healthcare – Not Just Hype Anymore

AI and machine learning has gotten a lot of attention over the last year, as it appears to be poised to become one of the biggest game changer in many industries, including the healthcare sector.

Read More

Q&A with Eric Lefkofsky, CEO of Tempus and Co-founder of Groupon

“Treating a cancer patient without the benefit of modern software is the same as driving at night without headlights”

Read More

PMWC Michigan – Big Data in Action: Data-Driven Insights in the Clinic

We are excited to launch the first Precision Medicine World Conference (PMWC) at the University of Michigan June 6-7, 2018.

Read More

Q&A with Susan A. Murphy, Harvard University

Q: Your lab develops experimental trial designs and data analysis methods for increasing the usefulness of mobile health interventions. Can you please give examples how these trials are being used in the areas of substance abuse, physical activity, or helping people quit smoking?

Read More

Q&A with Dr. Dara Richardson-Heron, Chief Engagement Officer, All of Us

Q: Your reputation for passion about engaging and empowering people precedes you. Can you please describe your role at the All of Us Research Program?

Read More
University of Michigan

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Changing Pharmacogenomics
    • Community Setting Challenges
    • Patient Issues and Challenges
    • Legal and Ethical Issues
    • Integrating genomic data into EMRs
    • Emerging Technologies
    • Personalized Health Care Delivery
    • Personalized Modeling of Precision Health
    • NIH’s All of Us Study
    • Big Data in Action
    • Opioid Precision Health
    • Neurosciences
    • Big Data in the Clinic
    • Wellness and Aging
    • Epigenetics and Aging
    • Precision Cancer Therapy
    • Data Sharing in Translational Medicine
    • Economic and Socio-political Issues

The 14th Precision Medicine World Conference (PMWC) will take place at the University of Michigan on June 6-7, 2018. This conference coincides with University of Michigan’s launch of a new Precision Health research initiative that integrates U of M’s strengths in Medicine, Engineering, Pharmacy, and Public Health. (hyperlink) This initiative combines biomedical expertise, big data, and the social sciences enabling a comprehensive approach to providing patients with tailored health solutions.

To support the University of Michigan’s goal to bring together leading researchers from across the university and the country to springboard this new and exciting research initiative, PMWC and U-M have agreed that the campus is an optimal location for the next conference. This forum will showcase practical content that helps close the knowledge gap among different sectors, thereby catalyzing cross-functional fertilization and collaboration to benefit both University of Michigan and PMWC attendees.

The program will feature innovative technologies, and analyze the success of already thriving initiatives and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advances in precision medicine and cutting-edge strategies and solutions that are fundamentally changing how patients are treated. This is reflected in the Program Theme: “Big Data in Action: Data-driven Insights in the Clinic”.

Agenda highlights:

    • More than 35 sessions with 100+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Two tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Changing Pharmacogenomics
        • Community Setting Challenges
        • Patient Issues and Challenges
        • Legal and Ethical Issues
        • Integrating genomic data into EMRs
        • Emerging Technologies
        • Personalized Health Care Delivery
        • Personalized Modeling of Precision Health
        • NIH’s All of Us Study
        • Big Data in Action
        • Opioid Precision Health
        • Neurosciences
        • Big Data in the Clinic
        • Wellness and Aging
        • Epigenetics and Aging
        • Precision Cancer Therapy
        • Data Sharing in Translational Medicine
        • Economic and Socio-political Issues

 

Confirmed thought leaders include:

Lee Hood

Lee Hood

Chief Science Officer, Providence Health

Eric Topol

Eric Topol

Chief Academic Officer, Scripps Health

Francis Collins

Francis Collins

Director of the National Institutes of Health (NIH)

Vicki L. Ellingrod

Vicki L. Ellingrod

Ass. Dir., Michigan Inst. for Clinical & Health Research

Goncalo Abecasis

Goncalo Abecasis

Chair, Department of Biostatistics, UM

Jeffrey Leiden

Jeffrey Leiden

Chairman, President and CEO, Vertex

Matthias Kretzler

Matthias Kretzler

Professor, Nephrology & Internal Medicine, UM

Arul Chinnaiyan

Arul Chinnaiyan

Professor of Pathology, Medical Institute, UM

David Ginsburg

David Ginsburg

Prof., Human Genetics; Investigator, UM

Steve Nelson

Steve Nelson

Chief Executive Officer, UnitedHealthcare

Gil Omenn

Gil Omenn

Dir., Comput. Med. & Bioinformatics Center, UM

Eric Lefkofsky

Eric Lefkofsky

Founder and CEO, Tempus

Steven Leeder

Steven Leeder

Dir., Clin. Pharmacology Children’s Mercy Hospital,(CMH)

Ariella Shikanov

Ariella Shikanov

Assistant Professor, Biomedical Engineering, UM

Lawrence Corey

Lawrence Corey

Presi. & Dir. Emeritus, Fred Hutch Cancer Research Cent.

Amir Dan Rubin

Amir Dan Rubin

President and CEO, One Medical

Isaac (Zac) Kohane

Isaac (Zac) Kohane

Professor of Pediatrics, Harvard University

Sachin Kheterpal

Sachin Kheterpal

Associate Professor, Anesthesiology, UM

Event Highlights

When
June 6, 2018 8:00am to June 7, 2018 5:00pm
Where
Ross School of Business
701 Tappan Ave
Ann Arbor, MI 48109
Cost
$774 by May 2nd, 2018

Registration: PMWC Conferences

Michigan June 6-7, 2018

First PMWC In Midwest
2 Track Speaker Lineup
Access to the exhibition
Breakfast & lunch refreshments
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help or to ask about the academic rate.